skip to Main Content
HACARUS Closes Series B Round – Raised 1.3 Billion Yen To Date

Strategic funding to further R&D activities as well as domestic and global business expansion. 

NOVEMBER, 16, 2020 – Kyoto, Japan – HACARUS, the leading provider of lightweight and explainable AI, is pleased to announce that it has closed its Series B financing round with additional funding from MTG Ventures, Resona Capital No. 6 Investment Business Association, PARKINSON Laboratories and the Japan Finance Corporation as well as follow-on investments by Ohara Pharmaceutical, Miyako Capital and Chushin Venture Capital – HACARUS has now raised 1.3 Billion Yen to date.

“We are in an expansive growth phase, and I am excited to welcome these strategic investors in our Series B round – with these strong partners supporting our mission I am confident that HACARUS will be able to achieve its goals” Said Kenshin Fujiwara, CEO and Founder. 

The raised funds will enable HACARUS to: 

(1) Strengthen R&D in materials informatics and drug discovery 

(2) Fuel Domestic & Global Business Expansion 

R&D Focused on Material Informatics & Drug Discovery

In recent years, AI has been increasingly applied in Materials Informatics, a method for materials development based on information science. However lengthy experiments are required to confirm the effectiveness – single experiments can take up to several months. Using its novel technology HACARUS is developing a method that combines human experience and intuition with its proprietary sparse modeling technology, to find the best new materials in the shortest possible time.

Another application for AI that has been growing is in the field of Drug Discovery. As in the case of Materials Informatics, experiments and human trials are required to confirm the efficacy and toxicity of a compound presented by AI, which takes several years. To remedy this, HACARUS is developing a sparse modeling based solution for Genomic Drug Discovery (a method for developing drugs with minimal side effects based on genomic information and patient response information), which will yield results quicker. 

The activities will be driven from the newly established Tokyo R&D center, and published in academic journals & presented at conferences before commercialized with industry partners. 

Domestic & Global Business Expansion

HACARUS provides a one-stop service for implementing AI, and has helped over 100 companies and organizations to date to achieve their AI goals. Through an extensive data science consulting service that ranges from business impact analysis, requirement definition, data analysis, data annotations, model development to application development, HACARUS is uniquely adept to provide best in class solutions. 

In addition to the consulting services, HACARUS also provides human resources development programs that equip firms with the know-how and skills required to successfully implement and continuously use AI technologies, and overcome common pitfalls. 

In an effort to meet a growing customer demand for its solutions HACARUS will also use the additional funding to expand its team at the Kyoto headquarters, Tokyo R&D Center, Kobe R&D Center and Manilla Development Center to support inquiries from an ever growing set of domestic and global clients. 

About HACARUS INC.

HACARUS INC., founded 2014 in Kyoto, Japan is the leading provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus’ proprietary AI engine is built using Sparse Modeling, an AI method that understands data like a human would – by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning. To learn more, visit https://hacarus.com